Search Abstracts Program

Session 27   Oral Abstract Session Hepatitis B and C Co-Infection Wednesday, 10 am - 11:15 am 6E

Moderator	David Thomas, Johns Hopkins Univ., Baltimore, MD
10:00 121.	Early HCV Viral Dynamics in HIV/HCV-Infected Patients on HCV Treatment F. J. Torriani*1, R. M. Ribeiro2, T. L. Gilbert1, U. M. Schrenk3, M. Clauson1, D. M. Pacheco1, and A. S. Perelson2 1Univ. of California, San Diego; 2Los Alamos Natl. Lab., NM; and 3Hoffmann La-Roche Pharmaceuticals, Basel, Switzerland Add to Itinerary
10:15 122.	HCV RNA Kinetic Response to PEG-Interferon and Ribavirin in HIV Co-Infected Patients K. E. Sherman*1, P. Horn1, S. Rouster1, M. Peters2, M. Koziel3, and R. Chung 4 for the ACTG 5071/5091 Study Group 1Univ. of Cincinnati, OH; 2Univ. of California, San Francisco; 3Beth Israel Deaconess Med Ctr., Boston, MA; and 4Massachusetts Gen. Hosp., Boston Add to Itinerary
10:30 123.	Adefovir Dipivoxil 10 mg Suppresses HBV Viral Replication in HIV/HBV Co-Infected Patients with Lamivudine Resistant HBV Y. Benhamou*1, M. Bochet1, V. Thibault1, V. Calvez1, M. H. Fievet1, M. Sullivan2, C. Brosgart2, H. Namini2, T. Poynard1, and C. Katlama1 1GH Pitié-Salpêtrière, Paris, France and 2Gilead Sci. Inc., Foster City, CA Add to Itinerary
10:45 124.	Anti-HBV Activity of Tenofovir Disoproxil Fumarate (TDF) in Lamivudine (LAM) Experienced HIV/HBV Co-Infected D. Cooper*1, A. Cheng2, D. Coakley2, J. Sayre2, L. Zhong2, S. S. Chen2, C. Westland2, M. Miller2, and C. Brosgart2 for the 907 Study Team 1NCHECR, Univ. of New South Wales, Australia and 2 Gilead Sci., Inc., Foster City, CA Add to Itinerary
11:00 125.	Antiretroviral Therapy and Mortality among HIV-Positive Liver Transplant Recipients M. Ragni*1, G. Neff2, N. Heaton3, M. Roland4, P. Stock4, A. Humar5, and J. Fung 1 1Univ. of Pittsburgh, PA; 2Univ. of Miami, FL; 3King's Coll., London, UK; 4Univ. of California, San Francisco; and 5Univ. of Minnesota, Minneapolis Add to Itinerary

---